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responders (p=0.03) and a higher rate of males (p=0.06) as well as pts with
previous myocardial infarction (p=0.06) in this group. There were no statisti-
cally significant differences in sex, BMI or diabetics.
Additional analysis of response versus weight showed an association with Pts
weighing less than 75kg who were more likely to be double responders
(p=0.02)
 Conclusion: Combined aspirin and clopidogrel non-responsiveness is
found in almost 12% of Pts. The only clinical predictor is weight>75kg.
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Purpose: Chronic total occlusion (CTO) remains one of the last frontiers
of percutaneous coronary intervention (PCI). Recently, a novel “soft”
guidewire (GW) developed for tracking invisible micro-channels (Fielder XT)
became available in France. The purpose of this study was to clarify the risk
factors contributing to PCI success for CTO lesions and evaluate the efficacy
and safety of this GW.
Methods: The study included 166 consecutive Pts with CTO’s (European
CTO Club definition) who underwent primary PCI at our institution between
June 2008 and Feb 2010 by 2 experienced operators. The cohort was divided
into 2 groups: group 1 (n=83), treated before availability of “Fielder XT” GW
in France and group 2 (n=83), treated since availability.
Results: Clinical and angiographic characteristics were similar in both
groups (age 63.9±11.3years, lesion length 23.0±18.1mm, bridging collateral
37.%, tortuosity score 0.16±0.37/1 and calcification score 0.94±1.08/3).
Fielder XT was used in 1 case (1.2%) in group 1 and 67 (80.7%) in group 2.
Micro catheters were used more frequently in group 2 (73.2% vs 56.6%;
p=0.013) and parallel wire technique was less required (16.2% vs 31.3%;
p=0.011). Angiographic success rate was significantly higher in group 2
(84.3% vs 67.5%; p=0.005) with a lower rate of dissection (12.2% vs 24.7%;
p=0.02) and a trend for a lower rate of perforation (4.9% vs 1.2%; p=ns). Pre-
dictors of failure in the total cohort were by multivariate logistic regression
analysis: proximal tortuosity (p=0.048, OR=3.15), absence of bifurcation
(p=0.024, OR=3.39), no visible stump (p<0.0001, OR=6.25), calcification
(p=0.029, OR=1.56) and patient in group 1 (p=0.015, OR=3.37).
Conclusion: Introduction of a dedicated “soft” wire in the CTO treatment
strategy improves the angiographic success rate of PCI with a more simple and
“soft” technique. Multivariate analysis confirmed classical independent predic-
tors of failure but also demonstrated that a new device may influence success
rate.
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Background: Premature discontinuation of antiplatelet therapy is a major
risk factor of stent thrombosis after drug-eluting stent placement leading to an
increased risk of death.
Objectives: We sought to determine by a simple questionnaire the preva-
lence of patients at risk for premature discontinuation of oral antiplatelet
therapy in elective percutaneous coronary intervention (PCI).
Methods: Patients scheduled for elective PCI underwent a routine inter-
view (RI) and a specific questionnaire (SQ) by two independent physicians the
day before the intervention. The SQ was designed to identify bleeding disor-
ders, suspected cancer, planned invasive procedures and self evaluation of
compliance. The final decision of drug eluting stent (DES) implantation was
made by a third independent physician who performed the planned PCI and
who had full access to the patient record. 
Results: At least one contraindication to DES implantation was found in
one third of the study population (82/302, 27%) after the RI. All these patients
were also identified by the SQ. At total of 31 additional patients were identi-
fied by the SQ as non eligible for DES implantation. Active bleeding (n=14)
and scheduled biopsies (n=4) were the two main contraindications to DES
implantation isolated by the SQ. Patients characteristics and angiographic find-
ings identified 59.9% patients (n=181/302) eligible for a DES implantation.
Finally the physician performing the PCI excluded 66.3% of the patients
(n=79/302) who could receive a DES and implanted a bare metal stent (BMS)
instead. This decision was based on the findings of the dedicated questionnaire
on top of the interview in 30 patients (38%) and in 49 patients (62%) for other
reasons.
Conclusions: In elective PCI, a simple questionnaire used before DES
implantation can improve identification of patients at high risk for premature
discontinuation of antiplatelet therapy.
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Background: Homocysteine has pro-thrombotic and pro-inflammatory
properties, it is a risk factor for cardiovascular disease. The prognostic value
of homocysteine in ST elevation myocardial infarction (STEMI) remains
uncertain. Aim: This study evaluates the predictive role of homocysteine level
on short and long term outcome in patients with STEMI. 
Methods and results: In this prospective cohort study, 186 consecutive
patients (mean age 58.4±12.6 years, 162 males, 65 diabetics) with STEMI
were enrolled. Plasma total homocysteine levels were measured within 24h
after admission. Inhospital complications: death, shock, left ventricular insuf-
Variable Double 
responders
Double 
non-responders
P
Male 191 (77.6%) 50 (86.2%) 0.15
Age(yrs) 67.3 +/-10.6 63.8+/-11.5 0.06
Weight (kg) 77.7+/-15.3 79.2+/-14.6 0.48
BMI 25.4+/-7.2 27.2+/-5.4 0.04
Smoking 89 (36.2%) 20 (35.5%) 0.81
Dyslipidaemia 152 (61.8%) 35 (61.4%) 0.96
Diabetes 52 (4.7%) 17 (6.1%) 0.22
Hypertension 159 (64.6%) 29 (50.1%) 0.06
Family history 18 (7.3%) 2 (3.5%) 0.20
Past PCI 88 (35.8%) 19 (33.3%) 0.73
Past CABG 9 (3.7%) 2 (3.5%) 0.96
Past MI 25 (10.1%) 11 (19.2%) 0.11
Weight <75kg 116 (46.8%) 18 (31.0%) 0.02
